

September 15, 2021



# Cellecstar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellecstar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview at the following upcoming conference:

## Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Presentation Date: Monday, September 20, 2021

Presentation Time: 12:25PM Eastern Time

Webcast Link: <https://wsw.com/webcast/oppenheimer16/clrb/2754601>

A replay of the presentation will be available on the [Events Page](#) of the company's website ([www.cellecstar.com](http://www.cellecstar.com)).

## About Cellecstar Biosciences, Inc.

Cellecstar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.

The company's product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The Company is currently enrolling in a global, pivotal Phase 2 Part B (CLOVER-WaM) expansion study in WM patients who have received at least two prior lines of therapy, including Bruton tyrosine kinase inhibitor failed or suboptimal response patients. The WM study will enroll up to 50 patients to evaluate the efficacy and safety of iopofosine for marketing approval.

For more information, please visit [www.cellecstar.com](http://www.cellecstar.com) and [www.wmclinicaltrial.com](http://www.wmclinicaltrial.com) or join the conversation by liking and following us on the company's social media channels: [Twitter](#), [LinkedIn](#), and [Facebook](#).

## **Forward-Looking Statement Disclaimer**

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes including our expectations of the impact of the COVID-19 pandemic. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan drug designation in the United States for iopofosine, the volatile market for priority review vouchers, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2020. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

## **Contact**

### **Investors:**

Monique Kosse  
Managing Director  
LifeSci Advisors  
212-915-3820

[monique@lifesciadvisors.com](mailto:monique@lifesciadvisors.com)



Source: Cellestar Biosciences